Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary PK of Cefepime-Taniborbactam in Healthy Subjects
NCT04951505Phase 1Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taniborbactam in hospital-acquired bacterial pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Venatorx Pharmaceuticals. Primary endpoint: Maximum Concentration in Epithelial Lining Fluid. Started Jun 2021; status: completed.
02
Drugs
taniborbactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04951505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951505.